FRUQUINTINIB

Brand name:

• Fruzaqla®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Metastatic colorectal cancer (mCRC)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New PBS listing (–)

Comment:

--

Submission sponsor:

TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.

Other PBAC consideration:

• FRUQUINTINIB

Submission received for:

September 2024 PBAC meeting

Opportunity for consumer comment:

Open 03/04/2024 and close 29/05/2024 (see PBS Website)

PBAC meeting:

Held on 06/09/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

14/02/2025

Lodgement of required documentation:

03/03/2025

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 02/12/2025

Status:

Finalised

Government processes:

Commenced on 11/12/2025

Medicine listed on the PBS:

01/05/2026 (see PBS schedule)

---